These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 36327103)

  • 1. Enhancing the Safety and Efficacy of PSMA-Based Small-Molecule Drug Conjugates by Linker Stabilization and Conjugation to Transthyretin Binding Ligand.
    Amin TU; Emara R; Pal A; Aldawod H; Jiang G; Liang D; Haque Tuhin MT; Balgoname A; Patel AD; Alhamadsheh MM
    J Med Chem; 2022 Nov; 65(22):15473-15486. PubMed ID: 36327103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PSMA-targeted small-molecule drug-conjugates with valine-citrulline and phosphoramidate cleavable linkers.
    Savoy EA; Olatunji FP; Fulton MD; Kesic BN; Herman JW; Romero O; Maniatopoulos M; Berkman CE
    Bioorg Med Chem Lett; 2024 Jan; 98():129573. PubMed ID: 38052377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody-drug conjugates in mice.
    Anami Y; Yamazaki CM; Xiong W; Gui X; Zhang N; An Z; Tsuchikama K
    Nat Commun; 2018 Jun; 9(1):2512. PubMed ID: 29955061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Basis of Valine-Citrulline-PABC Linker Instability in Site-Specific ADCs and Its Mitigation by Linker Design.
    Dorywalska M; Dushin R; Moine L; Farias SE; Zhou D; Navaratnam T; Lui V; Hasa-Moreno A; Casas MG; Tran TT; Delaria K; Liu SH; Foletti D; O'Donnell CJ; Pons J; Shelton DL; Rajpal A; Strop P
    Mol Cancer Ther; 2016 May; 15(5):958-70. PubMed ID: 26944918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of attachment site on stability of cleavable antibody drug conjugates.
    Dorywalska M; Strop P; Melton-Witt JA; Hasa-Moreno A; Farias SE; Galindo Casas M; Delaria K; Lui V; Poulsen K; Loo C; Krimm S; Bolton G; Moine L; Dushin R; Tran TT; Liu SH; Rickert M; Foletti D; Shelton DL; Pons J; Rajpal A
    Bioconjug Chem; 2015 Apr; 26(4):650-9. PubMed ID: 25643134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload.
    Wang Y; Fan S; Zhong W; Zhou X; Li S
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.
    Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z
    Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates.
    Caculitan NG; Dela Cruz Chuh J; Ma Y; Zhang D; Kozak KR; Liu Y; Pillow TH; Sadowsky J; Cheung TK; Phung Q; Haley B; Lee BC; Akita RW; Sliwkowski MX; Polson AG
    Cancer Res; 2017 Dec; 77(24):7027-7037. PubMed ID: 29046337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small Molecule-Drug Conjugates Emerge as a New Promising Approach for Cancer Treatment.
    Wang T; Li M; Wei R; Wang X; Lin Z; Chen J; Wu X
    Mol Pharm; 2024 Mar; 21(3):1038-1055. PubMed ID: 38344996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An Enzymatically Cleavable Tripeptide Linker for Maximizing the Therapeutic Index of Antibody-Drug Conjugates.
    Ha SYY; Anami Y; Yamazaki CM; Xiong W; Haase CM; Olson SD; Lee J; Ueno NT; Zhang N; An Z; Tsuchikama K
    Mol Cancer Ther; 2022 Sep; 21(9):1449-1461. PubMed ID: 35793453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Linkers Having a Crucial Role in Antibody-Drug Conjugates.
    Lu J; Jiang F; Lu A; Zhang G
    Int J Mol Sci; 2016 Apr; 17(4):561. PubMed ID: 27089329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix.
    Gébleux R; Stringhini M; Casanova R; Soltermann A; Neri D
    Int J Cancer; 2017 Apr; 140(7):1670-1679. PubMed ID: 27943268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates.
    Jeffrey SC; Torgov MY; Andreyka JB; Boddington L; Cerveny CG; Denny WA; Gordon KA; Gustin D; Haugen J; Kline T; Nguyen MT; Senter PD
    J Med Chem; 2005 Mar; 48(5):1344-58. PubMed ID: 15743178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
    Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
    Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates.
    Kågedal M; Gibiansky L; Xu J; Wang X; Samineni D; Chen SC; Lu D; Agarwal P; Wang B; Saad O; Koppada N; Fine BM; Jin JY; Girish S; Li C
    J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):537-548. PubMed ID: 28918591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing Lysosomal Activation of Antibody-Drug Conjugates (ADCs) by Incorporation of Novel Cleavable Dipeptide Linkers.
    Salomon PL; Reid EE; Archer KE; Harris L; Maloney EK; Wilhelm AJ; Miller ML; Chari RVJ; Keating TA; Singh R
    Mol Pharm; 2019 Dec; 16(12):4817-4825. PubMed ID: 31609629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Linker stability influences the anti-tumor activity of acetazolamide-drug conjugates for the therapy of renal cell carcinoma.
    Cazzamalli S; Corso AD; Neri D
    J Control Release; 2017 Jan; 246():39-45. PubMed ID: 27890855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecule- and peptide-drug conjugates addressing integrins: A story of targeted cancer treatment.
    Paulus J; Sewald N
    J Pept Sci; 2024 Jul; 30(7):e3561. PubMed ID: 38382900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A bifunctional molecule-based strategy for the development of theranostic antibody-drug conjugate.
    Xiao D; Zhao L; Xie F; Fan S; Liu L; Li W; Cao R; Li S; Zhong W; Zhou X
    Theranostics; 2021; 11(6):2550-2563. PubMed ID: 33456559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modular Smart Molecules for PSMA-Targeted Chemotherapy.
    Olatunji FP; Pun M; Herman JW; Romero O; Maniatopoulos M; Latoche JD; Parise RA; Guo J; Beumer JH; Anderson CJ; Berkman CE
    Mol Cancer Ther; 2022 Nov; 21(11):1701-1709. PubMed ID: 35999662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.